Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer

Blood

Volumn 106, Issue 5, 2005, Pages 1552-1558

  Kang, Yubin ^b   Xie, Litao ^b   Tran, Diane Thi ^b   Stein, Colleen S ^b   Hickey, Melissa ^b   Davidson, Beverly L ^b   McCray Jr , Paul B ^a  

^a UNIVERSITY OF IOWA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; BETA GALACTOSIDASE; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; COMPLEMENTARY DNA; GLYCOPROTEIN GP 64; LENTIVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOGRAPHA CALIFORNICA; BACULOVIRUS; CONTROLLED STUDY; EXPERIMENTAL MODEL; FELINE IMMUNODEFICIENCY VIRUS; FEMALE; GENE DELETION; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HEMOPHILIA A; HUMAN; LIVER CELL; MALE; MOUSE; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; TARGET CELL; TECHNIQUE; TISSUE DISTRIBUTION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS TYPING;

EID: 23944484509     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-11-4358     Document Type: Article

References (54)

1. Sadler J. Hemophilia A, Hemophilia B and von Willebrand's disease. In: Stamatoyannopoulos G, Nienhuis AW, Leder P, Majerus PW, eds. Molecular Basis of Blood Diseases. Philadelphia, PA: Saunders; 1987:575-630.
2. Hoyer LW. Hemophilia A. N Engl J Med. 1994;330:38-47.
3. Levine P. Clinical manifestations and therapy of hemophilia A and B. In: Colman R, Hirsh J, Marder V, Saizman E, eds. Hemostasis and Thrombosis. 2nd ed. Philadelphia, PA: JB Lippincott; 1987:97-111.
4. Fakharzadeh SS, Kazazian HH Jr. Correlation between factor VIII genotype and inhibitor development in hemophilia A. Semin Thromb Hemost. 2000;26:167-171.
5. Plug I, Van Der Bom JG, Peters M, et al. Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood. 2004;104:3494-3500.
6. Petrini P, Chambost H, Nemes L. Towards the goal of prophylaxis: experience and treatment strategies from Sweden, France and Hungary. Haemophilia. 2004;10(suppl 4):94-96.
7. Kaufman RJ. Advances toward gene therapy for hemophilia at the millennium. Hum Gene Ther. 1999;10:2091-2107.
8. Chuah MK, Collen D, VandenDriessche T. Gene therapy for hemophilia. J Gene Med. 2001;3:3-20.
9. VandenDriessche T, Vanslembrouck V, Goovaerts I, et al. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. Proc Natl Acad Sci U S A. 1999;96:10379-10384.
10. Stein CS, Kang Y, Sauter SL, et al. In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors. Mol Ther. 2001;3:850-856.
11. Powell JS, Ragni MV, White GC II, et al. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood. 2003;102:2038-2045.
12. Xu L, Gao C, Sands MS, et al. Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B. Blood. 2003;101:3924-3932.
13. Greengard JS, Jolly DJ. Animal testing of retroviral-mediated gene therapy for factor VIII deficiency. Thromb Haemost. 1999;82:555-561.
14. Park F, Ohashi K, Kay MA. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. Blood. 2000;96:1173-1176.
15. Kootstra NA, Matsumura R, Verma IM. Efficient production of human FVIII in hemophilic mice using lentiviral vectors. Mol Ther. 2003;7:623-631.
16. Park F. Correction of bleeding diathesis without liver toxicity using arenaviral-pseudotyped HIV-1-based vectors in hemophilia A mice. Hum Gene Ther. 2003;14:1489-1494.
17. Sarkar R, Tetreault R, Gao G, et al. Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood. 2004;103:1253-1260.
18. Chao H, Mao L, Bruce AT, Walsh CE. Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood. 2000;95:1594-1599.
19. Connelly S, Andrews JL, Gallo AM, et al. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood. 1998;9:3273-3281.
20. Andrews JL, Kadan MJ, Gorziglia MI, Kaleko M, Connelly S. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII. Mol Ther. 2001;3:329-336.
21. Gallo-Penn AM, Shirley PS, Andrews JL, et al. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs. Blood. 2001;97:107-113.
22. Lipshutz GS, Sarkar R, Flebbe-Rehwaldt L, Kazazian H, Gaensler KM. Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero. Proc Natl Acad Sci U S A. 1999;96:13324-13329.
23. Yant SR, Meuse L, Chiu W, Ivies Z, Izsvak Z, Kay MA. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNAtransposon system. Nat Genet. 2000;25:35-41.
24. Olivares EC, Mollis RP, Chalberg TW, Meuse L, Kay MA, Calos MP. Site-specific genomic integration produces therapeutic factor IX levels in mice. Nat Biotechnol. 2002;20:1124-1128.
25. Miao CH, Ye X, Thompson AR. High-level factor VIII gene expression in vivo achieved by nonviral liver-specific gene therapy vectors. Hum Gene Ther. 2003;14:1297-1305.
26. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263-267.
27. Kumar M, Keller B, Makalou N, Sutton RE. Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther. 2001;12:1893-1905.
28. DePolo NJ, Reed JD, Sheridan PL, et al. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol Ther. 2000;2:218-222.
29. Bums JC, Friedmann T, Driever W, Burrascano M, Yee J-K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammlian cells. Proc Natl Acad Sci U S A. 1993;90:8033-8037.
30. Johnston JC, Gasmi M, Lim LE, et al. Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J Virol. 1999;73:4991-5000.
31. Stein CS, Davidson BL. Gene transfer to the brain using feline immunodeficiency virus-based lentivirus vectors. Methods Enzymol. 2002;346:433-454.
32. Kramer MG, Barajas M, Razquin N, et al. In vitro and in vivo comparative study of chimeric liver-specific promoters. Mol Ther. 2003;7:375-385.
33. Swaroop M, Moussalli M, Pipe SW, Kaufman RJ. Mutagenesis of a potential immunoglobulin-binding protein-binding site enhances secretion of coagulation factor VIII. J Biol Chem. 1997;272:24121-24124.
34. Kang Y, Stein CS, Heth JA, et al. In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoprotein. J Virol. 2002;76:9378-9388.
35. Sinn PL, Hickey MA, Staber PD, et al. Lentivirus vectors pseudotyped with filoviral envelope glycoproteins transduce airway epithelia from the apical surface independently of folate receptor alpha. J Virol. 2003;77:5902-5910.
36. Kumar M, Bradow BP, Zimmerberg J. Large-scale production of pseudotyped lentiviral vectors using baculovirus GP64. Hum Gene Ther. 2003;14:67-77.
37. Beyer WR, Westphal M, Ostertag W, von Laer D. Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range. J Virol. 2002;76:1488-1495.
38. Wang G, Williams G, Xia H, et al. Apical barriers to airway epithelial cell gene transfer with amphotropic retroviral vectors. Gene Ther. 2002;9:922-931.
39. Wang G, Slepushkin VA, Zabner J, et al. Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect. J Clin Invest. 1999;104:R49-R56.
40. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995;10:119-121.
41. Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood. 2000;95:1324-1329.
42. Huser A, Rudolph M, Hofmann C. Incorporation of decay-accelerating factor into the baculovirus envelope generates complement-resistant gene transfer vectors. Nat Biotechnol. 2001;19:451-455.
43. Boyce FM, Bucher NL. Baculovirus-mediated gene transfer into mammalian cells. Proc Natl Acad Sci U S A. 1996;93:2348-2352.
44. Tani H, Limn CK, Yap CC, et al. In vitro and in vivo gene delivery by recombinant baculoviruses. J Virol. 2003;77:9799-9808.
45. Pearson MN, Rohrmann GF. Transfer, incorporation, and substitution of envelope fusion proteins among members of the Baculoviridae, Orthovectors myxoviridae, and Metaviridae (insect retrovirus) families. J Virol. 2002;76:5301-5304.
46. Hefferon KL, Oomens AG, Monsma SA, Finnerty CM, Bussard GW. Host cell receptor binding by baculovirus GP64 and kinetics of virion entry. Virology. 1999;258:455-468.
47. Brown BD, Shi CX, Rawle FE, et al. Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice. J Thromb Haemost. 2004;2:111-118.
48. Follenzi A, Battaglia M, Lombardo A, Annoni A, Roncarolo MG, Naldini L. Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood. 2004;103:3700-3709.
49. Schauber CA, Tuerk MJ, Pacheco CD, Escarpe PA, Veres G. Lentiviral vectors pseudotyped with baculovirus gp64 efficiently transduce mouse cells in vivo and show tropism restriction against hematopoietic cell types in vitro. Gene Ther. 2004;11:266-275.
50. Fields PA, Armstrong E, Hagstrom JN, et al. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice. Gene Ther. 2001;8:354-361.
51. Rawle FE, Shi CX, Brown B, et al. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains. J Gene Med. 2004;6:1358-1368.
52. Mingozzi F, Liu YL, Dobrzynski E, et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest. 2003;111:1347-1356.
53. Dobrzynski E, Mingozzi F, Liu YL, et al. Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer. Blood. 2004;104:969-977.
54. Miao HZ, Sirachainan N, Palmer L, et al. Bioengineering of coagulation factor VIII for improved secretion. Blood. 2004;103:3412-3419.